John Thomas, DO
Gastroenterology · Lincoln, NENPI 1265637151
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Boston Scientific at 53.1% of the total. 2025 is the largest year on record at $3,582, 6.4 times the $557 reported in 2019.
Across 241 payments — averaging $40.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Johnson & Johnson$805
- AbbVie$665
- Novo Nordisk$594
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$370
- Takeda Pharmaceuticals U.S.A., Inc.$338
- plus $2K from 25 others
Across 81 payments — averaging $11,454 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$928K
What the payments were for
- Travel & lodging$3,84439%
- Food & beverage$5,83459%
- Education$1532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 27 | $5,222 |
| Johnson & Johnson(2 entities) | 57 | $805 |
| AbbVie | 35 | $665 |
| Novo Nordisk | 7 | $594 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $370 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $338 |
| Janssen Scientific Affairs, LLC | 3 | $268 |
| Gilead | 10 | $186 |
| Aimmune Therapeutics, Inc. | 1 | $173 |
| Sanofi | 7 | $168 |
| Echosens North America, Inc. | 1 | $124 |
| Intercept Pharmaceuticals, Inc. | 6 | $91 |
| Bristol Myers Squibb | 5 | $82 |
| Merck | 5 | $78 |
| Olympus America Inc. | 1 | $70 |
| Pfizer | 5 | $68 |
| Madrigal Pharmaceuticals | 3 | $66 |
| Regeneron Healthcare Solutions, Inc. | 3 | $62 |
| Corcept Therapeutics | 1 | $60 |
| QOL Medical, LLC | 4 | $53 |
| Celltrion USA Inc. | 3 | $47 |
| Braintree Laboratories, Inc. | 3 | $45 |
| Lilly USA, LLC | 3 | $44 |
| Organon | 3 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Ardelyx, Inc. | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Apollo Endosurgery US Inc | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Apollo ESG NXT System$962
- OverStitch Endoscopic Suturing System$757
- OverStitch NXT Endoscopic Suturing System$648
- Wegovy$245
- STELARA$207
- VOWST$173
- Apollo 2-0 Polypropylene Endobariatric Suture$137
- FibroScan$124
- Skyrizi$118
- AXIOS$109
- REMICADE$105
How this compares
$9,831 in reported general payments places this provider in the 85th percentile of 89 gastroenterology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 17 | $458,163 |
| LinzessLinaclotide | 35 | $19,703 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 274 | $17,017 |
| Pantoprazole Sodium | 87 | $905 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 47 | $719 |
| Esomeprazole Magnesium | 24 | $694 |
| Azathioprine | 22 | $693 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 41 | $661 |
| Omeprazole | 39 | $630 |
| Ursodiol | 12 | $545 |
| Propranolol Hcl | 13 | $72 |
| Spironolactone | 15 | $46 |
| Furosemide | 11 | $11 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $805 | $458,16317 claims |
| AbbVieLinzess | $665 | $19,70335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 89 gastroenterology providers in Nebraska.
Other gastroenterology in Lincoln
- Mark GriffinLincoln$7K
- David LeeLincoln$4K
- Clark AntonsonLincoln$4K
- Michael RothLincoln$3K
- Matthew HrnicekLincoln$3K
- Christopher RifeLincoln$3K
- Erik BowmanLincoln$3K
- Paul PetersenLincoln$3K
- Sally KnooihuizenLincoln$2K
- James RoatLincoln$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.